Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies

NCT06137144 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06137144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06137144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 23, 2024
Completion date
May 3, 2029
Enrollment
161 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

aitl, alcl, hodgkin lymphoma, lymphoma, non-hodgkin lymphoma, peripheral t-cell lymphoma (ptcl), ptcl-nos